ABCL
Price
$2.72
Change
-$0.00 (-0.00%)
Updated
Nov 6, 10:49 AM (EDT)
111 days until earnings call
FATE
Price
$2.68
Change
-$0.08 (-2.90%)
Updated
Nov 5 closing price
117 days until earnings call
Ad is loading...

ABCL vs FATE

Header iconABCL vs FATE Comparison
Open Charts ABCL vs FATEBanner chart's image
AbCellera Biologics
Price$2.72
Change-$0.00 (-0.00%)
Volume$5.52K
CapitalizationN/A
Fate Therapeutics
Price$2.68
Change-$0.08 (-2.90%)
Volume$1.29M
CapitalizationN/A
View a ticker or compare two or three
ABCL vs FATE Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABCL vs. FATE commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a StrongSell and FATE is a Buy.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (ABCL: $2.72 vs. FATE: $2.68)
Brand notoriety: ABCL and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 193% vs. FATE: 110%
Market capitalization -- ABCL: $803.4M vs. FATE: $305.19M
ABCL [@Biotechnology] is valued at $803.4M. FATE’s [@Biotechnology] market capitalization is $305.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $488.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 6 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -3.89% price change this week, while FATE (@Biotechnology) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.94%. For the same industry, the average monthly price growth was +11.15%, and the average quarterly price growth was +8.66%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 25, 2025.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-0.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($803M) has a higher market cap than FATE($305M). FATE YTD gains are higher at: -28.342 vs. ABCL (-52.364). FATE has higher annual earnings (EBITDA): -176.34M vs. ABCL (-195.18M). ABCL has more cash in the bank: 670M vs. FATE (305M). ABCL has less debt than FATE: ABCL (72.1M) vs FATE (101M). ABCL has higher revenues than FATE: ABCL (33.1M) vs FATE (12.3M).
ABCLFATEABCL / FATE
Capitalization803M305M263%
EBITDA-195.18M-176.34M111%
Gain YTD-52.364-28.342185%
P/E RatioN/AN/A-
Revenue33.1M12.3M269%
Total Cash670M305M220%
Total Debt72.1M101M71%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLFATE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
75%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMXSX8.250.10
+1.23%
Federated Hermes Max-Cap Index Svc
NBFAX29.960.30
+1.01%
Neuberger Berman Focus Adv
CDIVX14.060.14
+1.01%
Copeland Dividend Growth Fund Class I
FSENX59.260.40
+0.68%
Fidelity Select Energy Portfolio
NRGEX68.31N/A
N/A
Neuberger Berman Genesis E

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with DNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then DNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
-5.88%
DNA - ABCL
57%
Loosely correlated
+4.72%
VCYT - ABCL
56%
Loosely correlated
+2.72%
PRME - ABCL
55%
Loosely correlated
+5.56%
ADPT - ABCL
54%
Loosely correlated
+6.08%
ARVN - ABCL
54%
Loosely correlated
+0.37%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.90%
ALLO - FATE
55%
Loosely correlated
-0.33%
ABCL - FATE
54%
Loosely correlated
-5.88%
NTLA - FATE
53%
Loosely correlated
+1.92%
BEAM - FATE
52%
Loosely correlated
-1.77%
CRBU - FATE
51%
Loosely correlated
+9.40%
More